oral contraceptive pill
Phase 3Small molecule
oral contraceptive pill is one of 37 small molecule programs targeting Polycystic Ovary Syndrome. It is currently in Phase 3.
1
Indications
3
Total Trials
0
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
175 competitors in Polycystic Ovary Syndrome
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaPhase 3
Glucophage
Boehringer IngelheimPhase 3
Clomid
FerringPreclinical
oral contraceptive pill
WWayne State University
Phase 3
Precose
BayerPreclinical
Proglycem
TevaPreclinical
Clomid
EMD SeronoPreclinical
Cetrotide
EMD SeronoPreclinical
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Tricor
JJagotec
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for oral contraceptive pill. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- WWayne State University